Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Abstract

leukemia. Blood 2008; 111: 2776–2784. 8 Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014; 28: 1774–1783. 9 DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T et… (More)
DOI: 10.1038/leu.2017.247

Topics

2 Figures and Tables

Cite this paper

@inproceedings{Hughes2017SustainedDM, title={Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results}, author={T. P. Hughes and Brian F. Leber and F. Cervantes and N. Spector and Reuben Pasquini and Nelma Cristina Diogo Clementino and Anthony P. Schwarer and P. E. Dorlhiac-Llacer and F-X Mahon and David Rea and Agn{\'e}s Guerci-Bresler and Suzane Kamel-Reid and Israel Bendit and S. Acharya and Tara Glynos and Deepan Dalal and Susan Branford and J. H. Lipton}, booktitle={Leukemia}, year={2017} }